A new method to prevent preterm birth using a vaginal drug delivery system.
N,N-Dimethylacetamide Vaginal Self-nanoemulsifying Drug Delivery System for the Prevention or Preterm Birth
['FUNDING_OTHER'] · ST. JOHN'S UNIVERSITY · NIH-11092332
This study is testing a new way to deliver a treatment that could help prevent preterm birth by reducing inflammation, and it's designed for pregnant individuals who are at risk of having their babies too early.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | ST. JOHN'S UNIVERSITY (nih funded) |
| Locations | 1 site (QUEENS, UNITED STATES) |
| Trial ID | NIH-11092332 on ClinicalTrials.gov |
What this research studies
This research investigates a novel vaginal self-nanoemulsifying drug delivery system that utilizes N,N-dimethylacetamide (DMA) to prevent preterm birth. The approach focuses on reducing inflammation, which is a major cause of preterm birth, by using DMA to inhibit certain inflammatory pathways. The study aims to develop a safe and effective method for delivering this treatment directly to the site of action, potentially improving outcomes for pregnant individuals at risk of preterm birth.
Who could benefit from this research
Good fit: Ideal candidates for this research are pregnant individuals at risk of preterm birth, particularly those with a history of preterm deliveries or signs of inflammation.
Not a fit: Patients who are not pregnant or those who have no risk factors for preterm birth may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly reduce the incidence of preterm births, leading to better health outcomes for newborns and lower healthcare costs for families and society.
How similar studies have performed: Previous research has shown promise in using DMA for preventing preterm birth in animal models, but this specific approach is novel and has not yet been tested in human subjects.
Where this research is happening
QUEENS, UNITED STATES
- ST. JOHN'S UNIVERSITY — QUEENS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: REZNIK, SANDRA EVE — ST. JOHN'S UNIVERSITY
- Study coordinator: REZNIK, SANDRA EVE
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.